A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Manhattan-based dentist Dr. Sandip Sachar and obesity medicine specialist Dr. Meghan Garcia-Webb discuss the prevalence of ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...